Evidence map›Paper›PMID 40675969›Full record

ArticleCell death & disease2025

NKD1 enhances colon cancer progression by inhibiting the autophagic degradation of MYC.

Wenbin Lu, Jianjun Tang, Yue Wang, Xiaoyan Gu, Hua Zhang, Yungang Liu, Ying Xiao, Qi Zhu, Jianzhong Deng, Ying Shen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wenbin Lu *Department of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
Jianjun Tang *Changzhou Key Laboratory of Molecular Diagnostics and Precision Cancer Medicine/Wujin Institute of Molecular Diagnostics and Precision Cancer Medicine of Jiangsu University, Changzhou, Jiangsu, 213017, China.
Yue Wang *Department of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
Xiaoyan GuDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
Hua ZhangDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
Yungang LiuDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
Ying XiaoDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
Qi ZhuDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
Jianzhong DengDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
Ying ShenDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
Anqi JiangDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
Yixin XuDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China.
Jianhua JinDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China. jianhuajin88@sina.com.
Yongzhong HouDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China. houyz@ujs.edu.cn.ORCID http://orcid.org/0000-0003-2019-8686
Qian LiuDepartment of Oncology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, 213017, China. liuqian@wjrmyy.cn.ORCID http://orcid.org/0000-0002-1574-6150

Funding

Changzhou Science and Technology Bureau (CZST) CJ20230007National Natural Science Foundation of China (National Science Foundation of China) 81872275
6 · The paper itself

Abstract

NKD1 is a known suppressor of the Wnt/β-catenin pathway. However, our previous study revealed that NKD1 could promote the proliferation and migration of colon cancer cells, enhancing colon cancer progression via unknown mechanisms. In the present study, we found that peroxisome proliferator-activated receptor δ (PPARδ) is a transcription factor of the NKD1 gene. By analyzing the differential protein expression profiles between SW620 and SW620-nkd1

Indexed as

AutophagyColonic NeoplasmsDisease ProgressionProto-Oncogene Proteins c-mycAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansPPAR deltaProteolysisSignal TransductionMYC protein, humanPPAR deltaProto-Oncogene Proteins c-myc

Identifiers

PMID40675969
PMCPMC12271375

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.